Amtagvi
(Lifileucel)Phase 3Cell therapy
This medication is a personalized cancer treatment made from your own immune cells. It is used to treat melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be surgically removed and hasn't responded to other treatments. The drug works by boosting your body's natural immune system to attack and destroy cancer cells.[1] Amtagvi is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Amtagvi is one of 160 biologic programs targeting Metastatic Melanoma. It is currently in Phase 3.
7
Indications
11
Total Trials
9
Active Trials
159
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
177 competitors in Melanoma
#DrugCompanyPhaseTrials
1Cotellic
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Taxol
TevaPhase 3
Mektovi
PfizerPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Lenvima
EisaiPhase 3
Opdualag
Bristol-Myers SquibbPhase 3
Talimogene Laherparepvec
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Melanoma4 trials
Tumor Infiltrating Lymphocytes1 trial
Endometrial Cancer1 trial
Melanoma1 trial
Melanoma, Cutaneous Malignant1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lifileucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 3[1]
- Company
- IIovance Biotherapeutics, Inc.